Physician lesson

Infusion and hypersensitivity reactions to anticancer drugs: management, rechallenge and desensitisation

Taxanes, platinums and antibodies; from grading to the 12-step protocol

Updated: 28 October 20261 min read2 references

Key points

  • Taxane and antibody reactions usually occur with the first or second dose and in the first minutes; platinum reactions usually come after several cycles (often from the sixth cycle onwards) [1].
  • Anaphylaxis: adrenaline 0.5 mg intramuscularly (1:1000), repeated every 5 to 15 minutes if needed [1].
  • Rapid desensitisation allows an essential drug to be continued [2].

Management by severity

Managing a reaction [1]
GradeSymptomsAction
1 (mild)Flushing, limited rashSlow down or pause briefly; antihistamine; continue at a lower rate
2 (moderate)Widespread hives, mild shortness of breath, blood pressure change not needing intensive treatmentStop; antihistamine, corticosteroid, oxygen; after recovery, continue at a lower rate with premedication
3 to 4 (severe or anaphylaxis)Bronchospasm, hypotension, angioedemaStop; intramuscular adrenaline, fluids, oxygen; usually permanent discontinuation or desensitisation

Desensitisation

In rapid desensitisation, the drug is given in 12 steps using three dilutions at increasing rates; of 413 desensitisations (mostly carboplatin and paclitaxel), 94% had no reaction or only a mild one, and there were no deaths [2]. It must be done in an equipped centre with a trained team. In carboplatin allergy, skin testing helps diagnosis and patient selection [1].

References

2 references
Show all referencesClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice GuidelinesRoselló S, Blasco I, García Fabregat L, et al · Ann Oncol · 2017;28:iv100-iv118
    DOIPubMed Back to text: 1 2 3 4
  2. 2
    Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 casesCastells MC, Tennant NM, Sloane DE, et al · J Allergy Clin Immunol · 2008;122:574-80
    DOIPubMed Back to text: 1 2

This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.